Important Short Interest Filing: Theravance Biopharma Ord (NASDAQ:TBPH) Could Burn Your Long Portfolio After More Shorts

November 17, 2016 - By Dolores Ford   ·   0 Comments

Important Short Interest Filing: Theravance Biopharma Ord (NASDAQ:TBPH) Could Burn Your Long Portfolio After More Shorts

The stock of Theravance Biopharma Ord (NASDAQ:TBPH) registered an increase of 5.12% in short interest. TBPH’s total short interest was 2.37 million shares in November as published by FINRA. Its up 5.12% from 2.25 million shares, reported previously. With 180,700 shares average volume, it will take short sellers 13 days to cover their TBPH’s short positions. The short interest to Theravance Biopharma Ord’s float is 8.55%. The stock closed at $33.58 during the last session. It is down 49.64% since April 15, 2016 and is uptrending. It has outperformed by 45.02% the S&P500.

Theravance Biopharma, Inc. is a biopharmaceutical company. The company has a market cap of $1.65 billion. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. It currently has negative earnings. The Firm operates in the segment of discovery , development and commercialization of human therapeutics.

Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.98, from 1.34 in 2016Q1. The ratio improved, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
Proshare Ltd Company holds 39,782 shares or 0.01% of its portfolio. Ellington Mngmt Gp Ltd Llc, a Connecticut-based fund reported 9,200 shares. Dekabank Deutsche Girozentrale has 24,500 shares for 0.01% of their US portfolio. Royal Bancorporation Of Canada has 10,210 shares for 0% of their US portfolio. The North Carolina-based Bancorporation Of America Corp De has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Barclays Public Ltd Com, a United Kingdom-based fund reported 13,489 shares. State Street Corporation reported 709,571 shares or 0% of all its holdings. Deere Communications holds 0.02% or 19,559 shares in its portfolio. Eam Investors Ltd Liability Com has invested 0.12% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Wells Fargo & Mn reported 12,331 shares or 0% of all its holdings. Blackrock last reported 3,821 shares in the company. Old West Inv Management Ltd has invested 0.71% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH). Geode Cap Management Ltd Liability last reported 245,586 shares in the company. Checchi Capital Advisers Lc holds 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH) for 2 shares. Ameritas Investment Partners Inc last reported 228 shares in the company.

Insider Transactions: Since August 18, 2016, the stock had 0 insider purchases, and 3 insider sales for $1.74 million net activity. Shafer Bradford J sold 49,122 shares worth $1.35M. HAUMANN BRETT K had sold 9,509 shares worth $265,967.

Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage

Out of 6 analysts covering Theravance Biopharma (NASDAQ:TBPH), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. Theravance Biopharma has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Robert W. Baird maintained it with “Neutral” rating and $14 target price in Wednesday, August 12 report. The firm has “Overweight” rating by Piper Jaffray given on Thursday, November 3. Evercore initiated it with “Buy” rating and $41 target price in Monday, August 29 report. The stock of Theravance Biopharma Inc (NASDAQ:TBPH) has “Underperform” rating given on Wednesday, October 12 by Robert W. Baird. The firm has “Buy” rating given on Monday, June 20 by Guggenheim. The rating was initiated by Leerink Swann with “Outperform” on Thursday, May 12.

TBPH Company Profile

Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.

More notable recent Theravance Biopharma Inc (NASDAQ:TBPH) news were published by: Fool.com which released: “Why Theravance Biopharma Inc Shares Tumbled 19.5% Today” on October 27, 2016, also Prnewswire.com with their article: “Theravance Biopharma to Report Third Quarter 2016 Financial Results on …” published on November 01, 2016, Prnewswire.com published: “Theravance Biopharma, Inc. Reports Third Quarter 2016 Financial Results and …” on November 08, 2016. More interesting news about Theravance Biopharma Inc (NASDAQ:TBPH) were released by: Prnewswire.com and their article: “Theravance Biopharma Announces Proposed Public Offerings of $100 Million of …” published on October 26, 2016 as well as Prnewswire.com‘s news article titled: “Theravance Biopharma Presents Interim Data from Ongoing Telavancin …” with publication date: October 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>